Share on StockTwits

Medivation (NASDAQ: MDVN) was the recipient of a ratings changes during the seven days:

  • Medivation had its price target raised by analysts at Credit Suisse from $95.00 to $98.00. They now have an “outperform” rating on the stock.
  • Medivation had its price target raised by analysts at Stifel Nicolaus from $83.00 to $89.00. They now have a “buy” rating on the stock.
  • Medivation had its price target raised by analysts at Brean Capital from $100.00 to $105.00. They now have a “buy” rating on the stock.
  • Medivation had its “outperform” rating reaffirmed by analysts at Keefe, Bruyette & Woods. They now have a $107.00 price target on the stock, up previously from $104.00.
  • Medivation had its price target raised by analysts at Leerink Swann from $104.00 to $107.00.
  • Medivation had its price target raised by analysts at Aegis from $125.00 to $130.00.

Medivation Inc (NASDAQ:MDVN) traded up 1.68% on Thursday, hitting $84.22. 1,147,639 shares of the company’s stock traded hands. Medivation Inc has a 52 week low of $48.15 and a 52 week high of $88.20. The stock’s 50-day moving average is $76.44 and its 200-day moving average is $71.66. The company has a market cap of $6.467 billion and a P/E ratio of 266.33.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.